Detection of tumour antigens in sera of patients with hepatocellular carcinoma using monoclonal antibodies.
A total of 70 serum samples taken from patients with hepatocellular carcinoma (HCC), acute viral hepatitis and cirrhosis and normal individuals were tested in a binding inhibition immunofluorescence assay using 5 mouse monoclonal antibodies (2G9, 3H11, 3H12, 1C7, 3H5) specific for hepatoma cells. Seven out of the 30 HCC sera (23.3%) inhibited the binding of one of these antibodies, 3H11. This detection of antigen 3H11 or antigens of similar structure in HCC sera was significantly more frequent than in control sera (1/40 = 2.5%) (Fisher's exact test, p = 0.009; df = 1, relative risk calculated by the odds ratio in a 2 x 2 table = 12.0). The presence of this antigen was unrelated to the hepatitis B surface antigen and alphafetoprotein status. Thus it would be of value particularly for the detection of hepatitis B negative or alphafetoprotein negative liver cancers.